2Morrow develops, licenses, and distributes behavioral digital health and DTx products. With over a dozen published studies and one of the few Phase III RCTs in digital health, 2Morrow takes an evidence-based approach to staying healthy. 2Morrow has employee wellness programs in a market that supports population wellness and well-being initiatives. 2Morrow has multiple products in the pipeline that expand on their work in substance use and for people living with chronic conditions.

2Strand is a data analysis service for genomics. Our professional data scientists act as employees for our clients. Biology researchers create projects as "competitions." Our professional data scientists solve the research questions. We provide a marketplace for life science researchers to hire data scientists on an as-needed basis. The customer is a life science researcher in need of getting their data analyzed but cannot afford hiring a full-time data scientist. Our focus is in the field of genomics and bioinformatics. Data scientists in this field, known as "bioinformaticians," undergo rigorous training in biology and computer science. They are an indispensable part of any research experiment in genomics. However, they can be expensive to hire. Our marketplace is a great place for bioinformaticians to meet researchers in need. Researchers hire bioinformaticians directly or can create "competitions" for multiple bioinformaticians to enroll in to answer harder questions.

4baseCare provides precision oncology solutions with advanced genomics to help cancer patients. The company focuses on leveraging advanced genomic technologies to provide personalized cancer treatment solutions. By analyzing the genetic profile of cancer patients, 4baseCare aims to identify targeted therapies that are more effective and have fewer side effects compared to traditional treatments. Their services include genomic testing, data interpretation, and personalized treatment recommendations, which are designed to improve patient outcomes and support healthcare providers in delivering precision medicine. The company collaborates with various stakeholders, including hospitals, research institutions, and pharmaceutical companies, to advance cancer care and research.

Access Vascular has developed a disruptive technology using a novel material process intended to significantly reduce the blood component accumulation (thrombosis or blood clotting) that leads to occlusions and infections. Over the last three years, Access Vascular’s technology has demonstrated the potential for superior clinical outcomes and lower healthcare costs compared with existing technologies. For patients, their solutions are predicted to decrease morbidity, shorten hospital stays, advance treatment, and minimize pain. Their technology has the potential to address a range of clinical needs in a variety of indications. Access Vascular is focused initially on launching their HydroPICC, a peripherally inserted central catheter with superior material performance over the current lagging technology.

Aevice Health provides non-invasive wearable technology that enables real-time monitoring of respiratory health. The devices facilitate early detection of cardiopulmonary issues and allow clinicians to track patient responses to treatment effectively. This approach enhances patient care by delivering critical insights directly from home.

Aksense develops a portable diagnostic biosensor for the diagnosis of healthcare-associated infections.

Alva Health develops healthcare wearables for remote stroke monitoring. The company's wearables are patented and operate round-the-clock to identify stroke signatures and connect consumers with emergency services. Alva Health aims to transform stroke treatment and the ability to create, validate, and market revolutionary neurotechnologies.

Anumana develops AI algorithms that analyze ECG data to support early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing tools that assist healthcare professionals in identifying potential heart issues. Anumana's platform extends beyond diagnostics, aiming to improve patient outcomes throughout the entire continuum of cardiovascular care, including perioperative and acute settings. By utilizing machine learning techniques, Anumana aims to refine screening processes, making it easier for clinicians to detect heart diseases and intervene promptly. This approach contributes to more efficient healthcare delivery and better management of cardiovascular health.

Aopia Biosciences is a biotechnology business focused on developing cutting-edge bioengineering solutions and technologies for biomedical research, diagnostics, and therapeutic applications.

Astek Diagnostics develops a platform that guides physicians in prescribing appropriate antibiotics for patients with bacterial sepsis in one hour. It employs a single-use cartridge to identify bacterial infection in the urine in substantially less time by detecting the oxygen consumption of bacterial species.

Atom Bioworks is a developer of a pattern-recognition enabled DNA-antibody-mimic rational design platform for sensing and therapeutics of infectious diseases.